ARK Invest's position in CRSP, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKK | 6,841,691 | $291.6M | 4.00% | #5 |
| ARKG | 2,363,478 | $100.7M | 5.10% | #4 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-12 | ARKG | Buy | Added | 43,887 | $2.3M |
| 2026-10-09 | ARKG | Buy | Added | 21,487 | $1.1M |
| 2026-09-09 | ARKK | Buy | Added | 36,352 | $1.9M |
| 2026-09-09 | ARKG | Buy | Added | 10,761 | $575K |
| 2026-09-08 | ARKK | Buy | Added | 85,317 | $4.7M |
| 2026-09-08 | ARKG | Buy | Added | 25,524 | $1.4M |
| 2026-07-29 | ARKK | Sell | Trimmed | 35,272 | $1.7M |
| 2026-07-28 | ARKK | Sell | Trimmed | 108,908 | $5.2M |
| 2026-05-18 | ARKG | Sell | Trimmed | 12,712 | $617K |
| 2026-03-13 | ARKK | Buy | Added | 38,608 | $1.9M |
| 2026-03-13 | ARKG | Buy | Added | 6,315 | $308K |
| 2026-03-12 | ARKK | Buy | Added | 96,488 | $4.7M |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs…
See CRSP's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open CRSP on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.